Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China

ObjectiveResults of CameL-sq has revealed the clinical benefits to patients with advanced squamous non-small-cell lung cancer (sq-NSCLC). This study aims to evaluate the cost-effectiveness of camrelizumab plus chemotherapy to treat sq-NSCLC from the perspective of the Chinese healthcare system.Metho...

Full description

Bibliographic Details
Main Authors: Taihang Shao, Yinan Ren, Mingye Zhao, Wenxi Tang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Public Health
Subjects:
cost-effectiveness analysis
camrelizumab
advanced squamous NSCLC
CameL-sq
China
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2022.912921/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2022.912921/full

Similar Items